Table 3. Clinical events at 12 months follow up in matched groups.

	SIERRA-75	Control	P
	N= 686	N= 686
Data are presented as n (%). BL: bleeding BARC 2-5; MI: myocardial infarction; ST: stent thrombosis; TLR: target lesion revascularization.
Co-Primary safety endpoints
Cardiac death/MI/ST	46 (6.7%)	56 (8.1%)	0.29
Bleeding BARC 2-5	51 (7.4%)	70 (10.2%)	0.04
Primary efficacy endpoint
Target lesion revascularization	12 (1.7%)	18 (2.6%)	0.25
Secondary endpoints
All cause death	50 (7.3%)	56 (8.2%)	0.53
Cardiac death	26 (3.8%)	30 (4.4%)	0.57
Myocardial infarction	25 (3.6%)	32 (4.6%)	0.35
Stent thrombosis definite/probable	10 (1.5%)	16 (2.3%)	0.23
All revascularizations	24 (3.5%)	32 (4.7%)	0.26
Stroke	7 (1%)	6 (0.9%)	0.84
Cardiac death/MI/ST/TLR	53 (7.7%)	64 (9.3%)	0.27
Cardiac death/MI/ST/TLR/BL	98 (14.3%)	127 (18.5%)	0.02